Allient (ALNT) Competitors $45.17 +0.50 (+1.12%) As of 12:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALNT vs. TXG, EYPT, TRNS, AEHR, CTKB, LAB, SENS, FEIM, QSI, and MASSShould you be buying Allient stock or one of its competitors? The main competitors of Allient include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), Quantum-Si (QSI), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Allient vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Transcat Aehr Test Systems Cytek Biosciences Standard BioTools Senseonics Frequency Electronics Quantum-Si 908 Devices Allient (NASDAQ:ALNT) and 10x Genomics (NASDAQ:TXG) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Is ALNT or TXG more profitable? Allient has a net margin of 2.75% compared to 10x Genomics' net margin of -13.13%. Allient's return on equity of 9.97% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets Allient2.75% 9.97% 4.67% 10x Genomics -13.13%-12.88%-10.03% Which has more volatility & risk, ALNT or TXG? Allient has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500. Does the media prefer ALNT or TXG? In the previous week, 10x Genomics had 10 more articles in the media than Allient. MarketBeat recorded 16 mentions for 10x Genomics and 6 mentions for Allient. 10x Genomics' average media sentiment score of 1.27 beat Allient's score of 1.06 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allient 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 10 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in ALNT or TXG? 61.6% of Allient shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 14.9% of Allient shares are held by insiders. Comparatively, 10.0% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings & valuation, ALNT or TXG? Allient has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllient$529.97M1.44$13.17M$0.8652.5210x Genomics$610.78M2.71-$182.63M-$0.70-19.02 Do analysts recommend ALNT or TXG? Allient currently has a consensus price target of $35.00, suggesting a potential downside of 22.51%. 10x Genomics has a consensus price target of $13.54, suggesting a potential upside of 1.72%. Given 10x Genomics' stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Allient.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allient 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.0010x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38 Summary10x Genomics beats Allient on 9 of the 16 factors compared between the two stocks. Get Allient News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNT vs. The Competition Export to ExcelMetricAllientELEC IndustryComputer SectorNASDAQ ExchangeMarket Cap$765.80M$5.34B$30.07B$9.85BDividend Yield0.26%2.66%3.16%4.49%P/E Ratio52.5324.74418.0026.51Price / Sales1.442.431,605.91161.56Price / Cash14.9622.9634.3228.92Price / Book2.652.349.166.51Net Income$13.17M$173.03M$808.33M$266.22M7 Day Performance-4.56%-1.42%-1.46%-1.21%1 Month Performance13.86%3.36%1.99%3.32%1 Year Performance117.69%18.10%24,023.82%23.49% Allient Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNTAllient3.6244 of 5 stars$45.17+1.1%$35.00-22.5%+116.1%$765.80M$529.97M52.532,525Positive NewsShort Interest ↓TXG10x Genomics4.2403 of 5 stars$14.01-1.9%$13.54-3.3%-42.1%$1.74B$610.78M-20.011,240Positive NewsEYPTEyepoint Pharmaceuticals2.3546 of 5 stars$11.57-0.3%$26.86+132.1%+47.1%$797.49M$43.27M-4.32120Positive NewsTRNSTranscat4.1026 of 5 stars$83.95-0.6%$112.20+33.7%-34.7%$782.34M$278.42M58.711,245Positive NewsAEHRAehr Test Systems2.3477 of 5 stars$24.95-7.8%N/A+81.5%$746.38M$58.97M-191.9190Positive NewsCTKBCytek Biosciences2.2545 of 5 stars$4.14-0.7%$5.60+35.3%-26.9%$526.71M$200.45M-82.80500Positive NewsLABStandard BioTools2.0817 of 5 stars$1.26-2.3%$1.55+23.0%-34.8%$481.31M$174.43M-3.94620Positive NewsSENSSenseonics1.7508 of 5 stars$0.46-0.1%$1.54+234.6%+20.8%$374.35M$25.47M-3.5390News CoverageGap UpFEIMFrequency Electronics2.1862 of 5 stars$32.25-1.7%N/A+127.8%$314.41M$69.81M13.06200Upcoming EarningsQSIQuantum-Si2.0698 of 5 stars$1.12-2.6%$3.48+210.3%+18.9%$226.79M$3.06M-1.65150Positive NewsMASS908 Devices3.3795 of 5 stars$6.25-0.2%$8.00+28.0%+48.4%$224.13M$59.63M-11.5760News Coverage Related Companies and Tools Related Companies 10x Genomics Alternatives Eyepoint Pharmaceuticals Alternatives Transcat Alternatives Aehr Test Systems Alternatives Cytek Biosciences Alternatives Standard BioTools Alternatives Senseonics Alternatives Frequency Electronics Alternatives Quantum-Si Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNT) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allient Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allient With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
